In this retrospective study, we demonstrate that both PSMA-PET and [18F]FDG-PET-derived molecular tumor volumes (PSMA-VOL and FDG-VOL) were significant negative prognosticators of survival in patients undergoing LuPSMA therapy. The gene discussed is FOLH1; the disease is neoplasm.